Abiopharma

Additional extension of the memorandum of understanding between Delek Israel and HOT Mobile until June 30, 2026

Share Buy Back - Daily Share Buy-Back Notice: Share Buy Back - Daily Share Buy-Back Notice

KKR Announces Intra-Quarter Update

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10)Advanced Triple-Negative Breast Cancer (TNBC)

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management

CMC Reports Third Quarter of Fiscal 2026 Results

Jacobs named supplier on UK government construction professional services framework

Results of the general meeting dated 25.6.26

Share Buy Back - Daily Share Buy-Back Notice: Daily Share Buy-Back Notice